Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.

Cancer Med · 2022 · PMC9678110 · PMID 35526267

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, HCC827 cells overexpressing mutant IDH1 protein showed a trend of resistance to erlotinib compared with those overexpressing wild‐type IDH1 protein (Figure 6C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.